Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 2
1965 40
1966 82
1967 83
1968 93
1969 119
1970 131
1971 134
1972 151
1973 153
1974 147
1975 154
1976 179
1977 121
1978 166
1979 204
1980 161
1981 193
1982 187
1983 216
1984 182
1985 206
1986 206
1987 182
1988 184
1989 249
1990 214
1991 184
1992 183
1993 153
1994 195
1995 188
1996 195
1997 179
1998 175
1999 167
2000 183
2001 203
2002 208
2003 306
2004 297
2005 387
2006 429
2007 417
2008 489
2009 551
2010 621
2011 602
2012 676
2013 675
2014 768
2015 800
2016 842
2017 1014
2018 1036
2019 1147
2020 1450
2021 1336
2022 1399
2023 1236
2024 1319
2025 1153
2026 399

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,935 results

Results by year

Filters applied: . Clear all
Page 1
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, Shi Y, Wang WH, Toth DP, Miller-Kassamali M, Cafone J, Jiang J, Li S, DeKlotz CMC, Nunes F, Lebwohl MG. Bissonnette R, et al. N Engl J Med. 2025 Nov 6;393(18):1784-1795. doi: 10.1056/NEJMoa2504187. N Engl J Med. 2025. PMID: 41191940 Clinical Trial.
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Gold LS, et al. Lancet. 2025 Sep 27;406(10510):1363-1374. doi: 10.1016/S0140-6736(25)01576-4. Epub 2025 Sep 18. Lancet. 2025. PMID: 40976249 Clinical Trial.
Editor's Highlights-February 2026.
Kemény L. Kemény L. Int J Dermatol. 2026 Feb;65(2):219-220. doi: 10.1111/ijd.70248. Epub 2025 Dec 31. Int J Dermatol. 2026. PMID: 41474006
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.
Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, Song EJ, Weirich O, Ceitlin RHG, Rubens JH, DeLozier AM, Ota T, Hsu MC, Li S, DeKlotz CMC, Nunes F, Warren RB. Gooderham M, et al. NEJM Evid. 2025 Dec;4(12):EVIDoa2500155. doi: 10.1056/EVIDoa2500155. Epub 2025 Nov 5. NEJM Evid. 2025. PMID: 41191932 Clinical Trial.
Editor's Highlights-June 2026.
Kemény L. Kemény L. Int J Dermatol. 2026 Jun;65(6):1131-1132. doi: 10.1111/ijd.70463. Epub 2026 May 2. Int J Dermatol. 2026. PMID: 42068165
Pipeline treatments on psoriatic disease.
Ribeiro AL, Leite LL, Micheroli R, Tovar-Batisdas DB, Gkini MA, Proft F. Ribeiro AL, et al. Best Pract Res Clin Rheumatol. 2025 Dec;39(4):102090. doi: 10.1016/j.berh.2025.102090. Epub 2025 Sep 22. Best Pract Res Clin Rheumatol. 2025. PMID: 40987667 Review.
French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.
Masson Regnault M, Brenaut E, Marniquet ME, Berthault C, Canoen L, Marcombes C, Melin A, Ouakrat R, Charles J, Mouret S, Potie O, Penso L, Vegas LP, Larid G, Roux M, Bougeard C, Sylvain S, Labonne C, Randriamiarana T, Pitaud DH, Etheve F, Gottlieb J, Gouillon L, Chastagner M, Sbidian E, Aubert H; Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). Masson Regnault M, et al. J Eur Acad Dermatol Venereol. 2026 Jun;40(6):963-979. doi: 10.1111/jdv.70263. Epub 2025 Dec 30. J Eur Acad Dermatol Venereol. 2026. PMID: 41469898 Free PMC article.
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors.
Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T. Blauvelt A, et al. J Am Acad Dermatol. 2026 Mar;94(3):802-809. doi: 10.1016/j.jaad.2025.11.033. Epub 2025 Nov 17. J Am Acad Dermatol. 2026. PMID: 41260526 Free article. Review.
22,935 results
You have reached the last available page of results. Please see the User Guide for more information.